OGI Stock Overview
Engages in the production and sale of cannabis and cannabis-derived products in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Organigram Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.66 |
| 52 Week High | CA$2.91 |
| 52 Week Low | CA$1.31 |
| Beta | 1.11 |
| 1 Month Change | 12.93% |
| 3 Month Change | -5.68% |
| 1 Year Change | 23.88% |
| 3 Year Change | -74.06% |
| 5 Year Change | -80.24% |
| Change since IPO | -80.72% |
Recent News & Updates
Organigram: Long Term Growth Improving With International And Domestic Cannabis Expansion (Rating Upgrade)
Dec 22Organigram Could Soar In 2026
Dec 01Recent updates
Organigram: Long Term Growth Improving With International And Domestic Cannabis Expansion (Rating Upgrade)
Dec 22Organigram Could Soar In 2026
Dec 01Organigram: Why I Still Like It
Sep 15Organigram: Q3 2024 Earnings Show Improvement In Revenues And Net Income (Hold)
Aug 14Organigram Has Declined A Lot And Is A Great Deal
Jun 23Organigram: Operating In A Structurally Challenged Industry
Apr 20Don't Rule Out A Bull Market (Podcast Transcript)
Aug 02Don't Rule Out A Bull Market
Jul 27Organigram revenue of $38.12M beats by $12.05M, sees Q4 revenue higher than Q3
Jul 14OrganiGram: Canadian Cannabis Remains Tough To Own
Apr 26Why OrganiGram Should Generate Consistent Growth Going Forward
Jan 16OrganiGram: Positive Signs, But Struggles Persist
Jul 14OrganiGram Holdings (OGI) Investor Presentation - Slideshow
Jun 16Organigram CEO Greg Engel to step down
May 03OrganiGram: The Hype Is Over
Apr 27Shareholder Returns
| OGI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.4% | -1.7% | -2.6% |
| 1Y | 23.9% | 3.2% | 24.5% |
Return vs Industry: OGI exceeded the US Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: OGI matched the US Market which returned 24.5% over the past year.
Price Volatility
| OGI volatility | |
|---|---|
| OGI Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OGI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OGI's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 898 | Beena Goldenberg | www.organigram.ca |
Organigram Holdings Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O’ Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings and dried flowers to other licensed producers.
Organigram Holdings Inc. Fundamentals Summary
| OGI fundamental statistics | |
|---|---|
| Market cap | US$204.68m |
| Earnings (TTM) | -US$31.55m |
| Revenue (TTM) | US$110.99m |
1.9x
P/S Ratio-6.8x
P/E RatioIs OGI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OGI income statement (TTM) | |
|---|---|
| Revenue | CA$159.84m |
| Cost of Revenue | CA$112.32m |
| Gross Profit | CA$47.52m |
| Other Expenses | CA$92.96m |
| Earnings | -CA$45.44m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 29.73% |
| Net Profit Margin | -28.43% |
| Debt/Equity Ratio | 0.03% |
How did OGI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 04:20 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Organigram Holdings Inc. is covered by 20 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Capital Markets |
| Tamy Chen | BMO Capital Markets Equity Research |